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Exercise Training Reduces Central Adiposity and Improves
Metabolic Indices in HAART-Treated HIV-Positive Subjects
in Rwanda: A Randomized Controlled Trial
EUGENE MUTIMURA,1,2 NIGEL J. CROWTHER,3 TODD W. CADE,4 KEVIN E. YARASHESKI,5
and AIMEE STEWART1,5
ABSTRACT
As HAART becomes more accessible in sub-Saharan Africa, metabolic syndromes, body fat redistribution
(BFR), and cardiovascular disease may become more prevalent. We conducted a 6-month, randomized con-
trolled trial to test whether cardiorespiratory exercise training (CET), improves metabolic, body composition
and cardiorespiratory fitness parameters in HAART-treated HIV African subjects with BFR. Six months of
CET reduced waist circumference (7.13  4.4 cm, p  0.0001), WHR (0.10  0.1, p  0.0001), sum skin-
fold thickness (6.15  8.2 mm, p  0.0001) and % body fat mass (1.5  3.3, p  0.0001) in HIVBFREXS.
Hip circumference was unchanged in non-exercise control groups. CET reduced fasting total cholesterol
(0.03  1.11 mM, p  0.05), triglycerides (0.22  0.48 mM, p  0.05) and glucose levels (0.21  0.71 mM,
p  0.05) (p  0.0001). HDL-, LDL-cholesterol and HOMA values were unchanged after CET. Interestingly,
HIV subjects randomized to non-exercising groups experienced increases in fasting plasma glucose levels,
whereas HIV seronegative controls did not (p  0.001). Predicted VO2 peak increased more in the
HIVBFREXS than in all other groups (4.7  3.9 ml/kg/min, p  0.0001). Exercise training positively mod-
ulated body composition and metabolic profiles, and improved cardiorespiratory fitness in HAART-treated
HIV Africans. These beneficial adaptations imply that exercise training is a safe, inexpensive, practical, and
effective treatment for evolving metabolic and cardiovascular syndromes associated with HIV and HAART
exposure in resource-limited sub-Saharan countries, where treatment is improving, morbidity and mortality
rates are declining, but where minimal resources are available to manage HIV- and HAART-associated car-
diovascular and metabolic syndromes. 
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INTRODUCTION
BODY COMPOSITION AND METABOLIC ABNORMALITIES associ-ated with body fat redistribution (BFR) (central adiposity
and/or peripheral lipoatrophy), glucose and lipid abnormalities,
and hypertension1 have been reported in approximately
20–60%2,3 of HIV-positive (HIV) patients receiving highly
active antiretroviral therapy (HAART).4 Although treatment
with potent HAART has improved the morbidity rate and well-
being of HIV patients accessing these therapies,5 HAART-
and HIV-related complications have been associated with in-
creased cardiovascular disease (CVD) and diabetes risks.6,7
Framingham risk equations suggest increased risk for myocar-
dial infarction8 and greater than a 20% increase in 10-year CVD
risk9 in HIV patients receiving HAART compared to age-
matched controls. Therefore HAART-treated HIV-infected pa-
tients represent an emerging population with increased risk for
CVD and diabetes.
1Faculty of Allied Health Sciences and Programs in HIV/AIDS Clinical Research and Community Interventions, Kigali Health Institute, Ki-
gali, Rwanda.
2School of Therapeutic Sciences, University of the Witwatersrand, Johannesburg, Republic of South Africa.
3Program in Physical Therapy and 4Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine,
St. Louis, Missouri 63130.
5Department of Chemical Pathology, National Health Laboratory Service, University of the Witwatersrand, Johannesburg, Republic of South
Africa.
In developing countries, BFR and metabolic abnormalities
have been reported in HAART-treated HIV patients10 and in
HIV-infected Africans receiving first line World Health Orga-
nization (WHO)-recommended HAART.11 As HAART be-
comes more accessible to HIV-infected people in resource-
limited regions of the world,12,13 and their quality of life im-
proves,14 the challenge is how to manage HIV- and HAART-
related metabolic syndromes. Subsequently, there is a growing
concern that CVD and diabetes risks, the main causes of mor-
bidity and mortality in the developed world, may emerge, along
with infectious diseases, as significant health concerns in HIV
individuals in sub-Saharan countries.15
Cardiorespiratory exercise training (CET) is an established,
cost-effective, and efficacious lifestyle modification that im-
proves insulin sensitivity16 and dyslipidemia17 and reduces cen-
tral adiposity or trunk fat,18 leading to an improved cardiovas-
cular and diabetic risk profile in HIV individuals from
Western countries.19 Consequently, regular CET has been rec-
ommended in the guidelines for management of HIV-related
dyslipidemia.20 Several nonrandomized controlled trials of aer-
obic and resistance exercise studies with small sample sizes and
short training durations have reported improvement in lipid and
body composition profiles in HIV individuals with BFR in
Western countries.21–27 In resource-limited areas such as sub-
Saharan Africa, CET may be a particularly important treatment
for BFR and metabolic disorders in HIV individuals taking
HAART. Therefore, we conducted a 6-month randomized con-
trolled trial to test whether CET improves metabolic and an-
thropomorphic parameters and enhances cardiorespiratory fit-
ness in HAART-treated HIV-infected African men and women
with BFR in Rwanda.
MATERIALS AND METHODS
Study population
Participants were screened for eligibility from August to De-
cember 2005 at the Centre Hospitalier Universitaire de Kigali,
Treatment and Research AIDS Centre, and HIV/AIDS clinics
of Kimironko, Kicukiro, Bilyogo-Nyiranuma, Kinyinya, and
Kacyiru health centers in Rwanda. Eligible HIV-positive vol-
unteers were between 21 and 50 years old and on a stable WHO-
recommended HAART regimen for 6 months. Participants
had moderate to severe BFR, determined by physical exami-
nation and subjects’ self reporting, and rating changes in fat
content using a validated questionnaire.28 The degree of body
fat redistribution was rated as absent (score 0), mild (noticeable
on close inspection, score 1), moderate (readily noticeable by
the patient and the physician, score 2), or severe (readily no-
ticeable to a casual observer, score 3). The overall score was
the mean of the scores given by the participant and a score as-
signed to each participant by a consensus of three clinicians
working in the field of HIV/AIDS. The presence and rating of
BFR were confirmed in all participants by physical examina-
tion, in which 18% of HIV participants who self-reported
moderate to severe BFR were excluded due to lack of confir-
mation from the clinicians. For the purposes of this study, a
clinical diagnosis was given to HIV participants with moder-
ate (score 2) to severe (score 3) BFR, and an overall mean score
of 18 on a validated seven-item inventory for the face, neck,
arms, breasts, abdomen, buttocks, and legs, with 21 as the high-
est score. All included HIV participants with BFR had a waist-
to-hip ratio (WHR) 0.90 in men and 0.85 in women.
Subjects were excluded if they had emotional distress or psy-
chosis, unstable angina, shortness of breath with exercise, a
known medical history that would contraindicate exercise train-
ing, acute infections, or AIDS-defining opportunistic illnesses.
Subjects were also excluded if they were obese [body mass in-
dex (BMI)  32 kg/m2], had musculoskeletal or neuromuscu-
lar disorders, participated in regular exercise (3 sessions/
week, 30 min/session in the previous 4 weeks), were unwill-
ing to exercise continuously for 6 months, or anticipated
changes in HAART medications or were currently taking med-
ications that affect lipid and glucose metabolism. Pregnant or
breast-feeding women were excluded. Participants were re-
ceiving WHO-recommended first line HAART regimens, with
80% receiving stavudine, lamivudine, and nevirapine, a widely
used first-line therapy in resource-limited regions of the world.
Another 11% received zidovudine, lamivudine, and nevirapine
and 5% received zidovudine, lamivudine, and efavirenz. A
small percentage of subjects (3%) received stavudine, lamivu-
dine, and efavirenz and only 1% received lamivudine, abacavir,
and nevirapine. HAART regimen use was not different among
the HIV participant groups.
One hundred and fifty-two HIV participants with moderate
to severe BFR were screened and 52 were not eligible; 21 par-
ticipants did not meet eligibility criteria for central obesity, 16
participants were determined unfit for the exercise program, 11
participants declined to participate, three anticipated changes in
HAART medications, and one participant had epilepsy. 
One hundred HIV participants with moderate to severe BFR
were stratified by gender and randomized to either an exer-
cise group (n  50; HIVBFREXS) or a nonexercising control
group (n  50; HIVBFRnoEXS). For comparative purposes,
we also randomly recruited age, gender, and BMI-matched HIV-
infected participants on stable HAART for 6 months, without
BFR changes (as defined above) (n  50; HIVnoBFR
noEXS). Since there are few normative data on cardiorespiratory
fitness and metabolic and body composition parameters in HIV-
seronegative Rwandan adults, we also randomly recruited age,
gender, and BMI-matched HIV-seronegative healthy adults as an
additional comparative control group (n  50; HIV-venoEXS).
After obtaining ethical permission from the National Research
Ethics Committee (Rwanda), written informed consent was ob-
tained from all volunteers before participation.
Metabolic and anthropometrics
After an overnight fast, a venous blood sample was obtained
and serum was isolated and analyzed for total cholesterol, high-
density lipoprotein cholesterol (HDL cholesterol), triglycerides
(TG), and glucose and insulin levels (Humalyzer 3000; Abbott
Laboratories, Abbott Park, IL). The CD4 count was quanti-
fied by flow cytometry using monoclonal antibodies (Simultest
CD4, Beckon Dickinson). Low-density lipoprotein cholesterol
(LDL cholesterol) was calculated from total cholesterol, HDL
cholesterol, and TG using the Friedewald formula.29
Height, weight, and hip and waist circumferences were mea-
sured while the participant was standing, wearing light clothing
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and no shoes. Height and weight were measured to the nearest
0.1 kg and 0.1 cm, respectively. Waist and hip circumferences
were assessed by two well-trained research associates. For re-
producibility and to minimize interobserver variability, associ-
ates were trained on proper anatomic placement of the tape mea-
sure, and their measurements were cross-validated on a number
of participants until the variability between duplicate measures
among associates was minimal. Waist circumference was mea-
sured using a cloth tape measure at the narrowest circumference,
halfway between the lowest ribs and iliac crests. Hip circumfer-
ence was measured at the level of the anterior superior iliac spine,
where this could be palpated, or at the broadest circumference
below the waist. Two measurements were taken; if they differed
by 2 cm, a third measurement was taken and the mean of the
closest two measurements was used to calculate waist-to-hip ra-
tio (WHR). Mid-triceps, mid-biceps, suprailiac, and subscapular
skinfolds were measured using Lange skinfold callipers. For re-
producibility, an experienced trained investigator (E.M.) located
and measured all skinfolds in triplicate. Measurements were read
to the nearest 0.2 mm and averaged for each skinfold site. The
sum of four total skinfold measures was used to calculate per-
centage body fat (% BFM) and lean body mass (% LBM) using
equations and formulas30,31 validated in a black population.32 All
measurements were obtained at baseline and after 6 months of
observation, placebo, or exercise intervention.
Exercise training protocol
HIVBFREXS participated in a 6-month, supervised ex-
ercise training program (3 sessions/week, 1.5 h/session, alter-
nating days) at Amahoro Fitness Club located in downtown Ki-
gali. All participants were instructed on a progressive exercise
program consisting of stretching exercises and 15 min of brisk
walking followed by 45–60 min of jogging, running, stair
climbing, low back and abdominal stabilization, and strength-
ening exercises. Participants were instructed to perform pri-
marily jogging and running exercises with a goal of achieving
at least 45% age-predicted maximal heart rate (HR) in the first
3 weeks, 60% age-predicted maximal HR in the next 6 weeks,
and 75% age-predicted maximal HR by the end of the inter-
vention. Heart rate was approximately assessed in one-third of
participants in each training session with all participants age-
predicted maximal HR assessed at least every week. This en-
sured that the exercise stimulus was adequate to elicit car-
diorespiratory and musculoskeletal system adaptations. Each
exercise training session ended with 15 min of cool down and
stretching exercises. Participants’ attendance at each session
was recorded and noncompliance was defined as 50% missed
training sessions. Cardiorespiratory fitness was assessed at
baseline and 6 months later using the 20-m multistage shuttle
run test (20mMST)33 to predict maximum oxygen consumption
(VO2 peak; ml/kg/min). During the 20mMST, participants ran
continuously in an indoor fitness stadium on a flat hard syn-
thetic surface between two points separated by 20 m at a pace
that was incremented by 0.14 m/sec each minute or level. The
required running pace was indicated by verbal cues and prere-
corded audio signals that sounded when each 20-m “lap” should
have been completed (much like a metronome). The inability
to maintain the required pace for a particular increment was
documented (level and number of 20-m laps completed) and
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FIG. 1. Flow of participants through the trial; 21 did not meet the criteria for central obesity, 11 were determined unfit to ex-
ercise, 11 declined to participate, three anticipated changes in HAART regimens, and one had a neurological disorder.
represents the participants’ maximal effort, which is propor-
tional to VO2 peak. The 20mMST assessment tool for car-
diorespiratory fitness and exercise capacity has been validated
in health and fitness settings.34 Each participant’s cardiorespi-
ratory fitness was assessed individually during the 20mMST to
minimize possible sources of error. Heart rate and blood pres-
sure were taken immediately before and after the exercise test,
and perceived exertion was evaluated with the Borg Rating of
Perceived Exertion Scale (Borg RPE).
Three HIVBFREXS participants did not complete the
CET program: two dropped out, one died following surgery,
and another one changed jobs to a distant location. One
HIVBFRnoEXS participant was lost to follow-up and
three HIVnoBFRnoEXS subjects dropped out; one de-
clined further participation and two started to obtain med-
ications and social support from a rural nongovernmental or-
ganization. Seven HIV-venoEXS participants declined
further participation due to lack of time, interest, family is-
sues, or personal travel arrangements. Compliance with the
exercise program was 82.2%. Figure 1 represents a flow di-
agram of study subjects.
Statistical analyses
Based on previous studies,22–24 we estimated that a sample
of 37 individuals in each group would have a power of 90% to
detect a 10% difference in triglycerides and total cholesterols
for   0.05. Assuming a drop-out of 20% per group, at least
44 participants would be required per group. Since all subject
groups were 44 per group after the intervention, the primary
efficacy analyses were based on data from participants who
completed the study at a 6-month period.
Between-group comparisons of the changes in the out-
come variables were performed using analyses of covariance 
(ANCOVA). Analyses of covariance with the 6 month change
as the dependent variable (absolute change from baseline), the
treatment group as the independent variable, and baseline val-
ues as the covariates, were used to determine whether there
were between-group differences at 6 months after adjusting for
the initial baseline values. As part of the ANCOVA, statistical
contrasts were used to make pairwise comparisons across
groups. All analyses were performed using SAS software, ver-
sion 9.1.3 of the SAS System for Linux (SAS Institute Inc.,
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TABLE 1. BASELINE CHARACTERISTICS, BODY COMPOSITION, AND METABOLIC DATAa
HIVBFRnoE XS HIVBFREXS p
Age (years) 37.5  6.90 37.8  5.50 0.807
Number (% females) 50 (60) 50 (60) —
CD4 cell count (cells/l) 348  162 353  168 0.882
Height (m) 1.63  0.10 1.64  0.10 0.898
Weight (kg) 64.8  5.70 65.6  10.4 0.891
HAART duration (weeks) 62.7  27.6 71.4  36.7 0.671
BFR score(7-item) 18.7  2.30 19.3  2.10 0.882’
Body composition
Body mass index 24.4  2.70 24.0  3.10 0.406
(kg/m2)
Waist (cm) 92.3  6.90 91.0  8.40 0.341
Hip (cm) 93.7  6.80 92.3  7.60 0.183
Waist-to-hip ratio 0.98  0.00 0.99  0.10 0.796
Skinfold (mm)
Triceps 14.4  3.40 14.4  3.90 0.979
Biceps 10.8  2.40 10.7  72.9 0.848
Subscapular 18.7  4.90 18.6  5.20 0.884
Suprailiac 18.8  5.10 18.7  5.50 0.915
Total skinfolds 62.7  12.9 62.3  15.0 0.888
Body fat mass (%) 29.3  4.30 29.4  6.20 0.928
Metabolic
Total cholesterol 3.89 (1.04) 3.78 (0.93) 0.499
(mmol/liter)
HDL cholesterol 1.27 (0.15) 1.28 (0.19) 0.684
(mmol/liter)
LDL cholesterol 2.16 (0.77) 2.10 (0.74) 0.659
(mmol/liter)
Triglyceride (mmol/liter) 1.34 (0.36) 1.33 (0.39) 0.941
Glucose (mmol/liter) 4.95 (0.74) 4.76 (0.76) 0.191
Insulin (mol/liter) 59 (28) 67 (29) 0.131
HOMA 1.87 (0.13) 2.04 (0.14) 0.196
aData expressed as mean  SD or median (interquartile range); BFR score(7-item), 7-item body fat redistribution score; HOMAIR,
homeostasis model assessment of insulin resistance.
Cary, NC). All statistical tests were two-tailed, and significance
was accepted at a p-value  0.05. Data are presented in tables
as arithmetic mean  SD, or median (interquartile range), and
in figures as mean  SE, unless stated otherwise.
RESULTS
Cardiovascular outcomes
At baseline, participants with BFR randomized to the exer-
cise or nonexercise group were well matched for age, CD4 cell
count, body fat redistribution score, gender, body composition,
and metabolic variables (Table 1). HIV-seronegative controls
had lower diastolic blood pressure at the start of the 20mMST
than HIVnoBFRnoEXS subjects (p  0.05). At 6 months,
HIVBFREXS achieved a significantly higher HR and RPE
at the end of the 20mMST (p  0.001) than other subject
groups. Likewise, predicted VO2 peak during the 20mMST in-
creased more in the HIVBFREXS group (4.7  0.56
ml/kg/min, p  0.0001) than in all other groups (Fig. 2). Fol-
lowing CET, the mean changes in CD4 cell count for
HIVBFREXS (19  91 cells/l) were not significantly dif-
ferent from that of HIV-infected subjects with BFR in the
HIVBFRnoEXS (34  128 cells/l) (p  0.547) or
HIVnoBFRnoEXS subjects (77  160 cells/l) (p  0.079).
Body composition outcomes
After 6 months of CET, BMI, waist circumference (	7.13 
4.4) (Fig. 3) and WHR declined more in HIVBFREXS, while
it remained unchanged or increased in the other groups (Table
2). Hip circumference was unchanged after 6 months in all
groups; therefore the decline in waist-to-hip ratio in
HIVBFREXS was attributed to the decline in waist circum-
ference. In fact, waist circumference increased 1.84  9.2 cm
in HIVnoBFRnoEXS subjects. We also observed a decline
in WHR in HIVBFRnoEXS participants compared to HIV-
venoEXS participants (0.00  0.1 versus 0.01  0.1; p 
0.05). After the CET, waist circumference in the exercise group
was not different from that of HIV-seronegative subjects (Table
2). The BFR mean score significantly declined more in
HIVBFREXS than HIVBFRnoEXS, while the BFR mean
score significantly increased in HIVnoBFRnoEXS (Table 2).
Subscapular (	1.9  3.2 mm), suprailiac (	2.13  3.5 mm),
and sum skinfold thicknesses (	6.15  8.2 mm) (Fig. 3) de-
clined more in HIVBFREXS than in all other groups (p 
0.0001). HIVBFREXS experienced a significant decrease in
% BFM (	1.5  3.3, p  0.001) and a significant increase in
% LBM (1.5  3.1, p  0.0001) compared to all other groups
(Table 2).
Metabolic outcomes
At baseline, total cholesterol was significantly greater in
HIVBFREXS and HIVBFRnoEXS than HIVnoBFR
noEXS and HIV-venoEXS (Table 3). Following CET, total
cholesterol levels declined more in the HIVBFREXS group
than the HIVBFRnoEXS group (p  0.05). HIV-venoEXS
showed significantly lower mean changes in total cholesterol
than HIVBFREXS (p  0.0003). There were no significant
changes in HDL cholesterol, LDL cholesterol, and HOMA val-
ues, but insulin levels declined more in the HIVBFREXS
than in the HIVBFRnoEXS group (Table 3). Subjects in the
exercise group demonstrated a significant decrease in fasting
plasma glucose than HIV subjects with BFR in the nonexer-
cise group [	0.21 (0.71) versus 0.39 (1.25), p  0.0001] and
HIVnoBFRnoEXS subjects (p  0.002) (Fig. 3). Interest-
ingly, HIV-infected subjects with BFR- and HIV-infected sub-
jects with no BFR in the nonexercise groups had a significant
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FIG. 2. Mean change in VO2 peak predicted from a 20-m multistage shuttle run test. **p  0.0001 versus HIVBFREXS
group; BFR, body fat distribution; VO2 peak max, maximum total body oxygen consumption; HIV-venoEXS, HIV-seronega-
tive controls; HIVnoBFRnoEXS, nonexercise HIV subjects with no BFR; HIVBFRnoEXS, nonexercise HIV subjects
with BFR; HIVBFREXS, HIV subjects with BFR in the exercise group.
increase in fasting plasma glucose, whereas HIV-seronegative
subjects did not. Also the serum TG level declined more in
HIVBFREXS than in HIVBFRnoEXS and was not
changed in other subject groups (Time 3, Fig. 3).
DISCUSSION
Our findings indicate that CET positively modulates body
composition, decreasing waist circumference, waist-to-hip ra-
tio, and percentage body fat mass in WHO-recommended
HAART-treated HIV African subjects with BFR in Rwanda.
Exercise training further modulates a decline in total serum cho-
lesterol, TG, and glucose, and also improves cardiorespiratory
fitness. To our knowledge, this is the first study to demonstrate
that CET is safe, practical, and effective at reducing central adi-
posity and cardiovascular risk factors and improving cardio-
vascular fitness in HAART-treated HIV sub-Saharan Africans
with body fat alterations. Previous studies on the effects of CET
on metabolic and anthropomorphic abnormalities in HAART-
treated HIV patients were limited by small sample sizes, were
disproportionate with respect to gender, and were not largely
controlled.21–25 We believe our findings are particularly im-
portant due to increasing access to HAART in sub-Saharan
countries and the potential for increased CVD and diabetes risks
for HIV patients starting HAART.
HIV-infected participants with BFR who exercised showed
a significant improvement in body composition, particularly re-
sulting in a considerable reduction in waist circumference and
WHR and an increase in lean body mass. Exercise training did
not significantly affect hip circumference, but reduced waist cir-
cumference, which accounted for the decline in WHR. Both
waist circumference and WHR are simple and inexpensive mea-
surements used in normal populations to assess central adipos-
ity, and are good predictors of CVD and diabetes risks.35
Elevated WHR in HAART-treated HIV-infected individuals
is mainly due to a gradual increase in waist circumference rather
than to changes in hip circumference.36 Our findings further
showed that sedentary HAART-treated HIV African partici-
pants had an increase in waist circumference over time in com-
parison to age-, gender-, and BMI-matched HIV-seronegative
participants. Others have reported a gradual increase in waist
MUTIMURA ET AL.20
FIG. 3. Mean changes in sum skinfolds, waist circumference, triglycerides, and fasting glucose in 6 months. *p  0.05, **p 
0.0001 versus all subject groups; p  0.004 versus the HIVBFREXS group; p  0.0001 versus the HIVBFRnoEXS


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































circumference in HIV patients with body fat redistribution.36
The cause and existence of this HIV- and HAART-associated
central adiposity are under debate.37 Our findings suggest that
waist girth increased over 6 months in HIV-infected African
subjects treated with HAART, and that it is preventable with 6
months of aerobic exercise training. Further, the current study
supports other studies that found a relationship between reduc-
tions in waist circumference and WHR and increases in lean
body mass and reductions in body fat mass in subjects who par-
ticipated in CET.22,23
Exercise training induced alterations in central adiposity and
glucose and lipid parameters in the current study, and this trans-
lates to reduced cardiovascular disease risk in HAART-treated
HIV-infected Africans, as seen in HIV-seronegative popula-
tions.38 Exercise training reduces fat mass and increases fat-
free mass in other HIV cohorts;21–24 our findings support this
notion and further indicate that CET attenuates fasting serum
glucose and TG and improves cardiorespiratory fitness in
HAART-treated HIV African men and women with body fat
alterations. Thus, TG may reduce CVD morbidity and mortal-
ity rates and improve insulin sensitivity in HAART-treated
HIV African men and women39 through its reduction of cen-
tral adiposity, a strong predictor of insulin resistance in HIV
patients.40
In the current study, exercise training improved the car-
diorespiratory fitness of HIV African men and women with
body fat alterations. At baseline, we did not observe differences
in exercise capacity between HIV African subjects with or
without body fat changes; however, when combined as one
group, all HIV-infected subjects had lower baseline VO2max
(ml/kg/min) compared to HIV-seronegative African control
subjects. Cardiorespiratory fitness improved 19% in HIV-in-
fected African subjects who exercised for 6 months, but did not
achieve the value of the healthy, normal HIV-seronegative
African controls in the current study. Lower cardiorespiratory
fitness has been reported in HIV-infected subjects irrespective
of HAART use,41 but improves with exercise training.25,42,43
This may further indicate inadequate aerobic capacity in HIV
people, possibly due to the effects of HIV disease or HAART
on tissue oxygen extraction and utilization. Low cardiorespira-
tory fitness has been associated with elevated cardiovascular
disease morbidity and mortality, as a result central obesity and
other risk factors in non-HIV-positive populations.44
The current study is limited by lack of more objective fat
quantification methods, such as dual energy X-ray absorptiom-
etry (DEXA) or magnetic resonance imaging (MRI) and com-
puted tomography (CT) scans. Although expensive for large
sample sizes, the use of MRI and/or CT scans would reveal the
direct effects of exercise on visceral and subcutaneous fat con-
tent. Anthropometric measurements have proven sensitive and
useful in assessing body composition changes in HIV-infected
people.36 Further randomized controlled studies evaluating the
effects of exercise training using modern body composition as-
sessment tools are warranted, particularly in subjects whose
metabolic variables indicate greater cardiovascular disease risk.
In summary, our findings provide evidence that exercise
training is safe, practical, and efficacious in reducing central
adiposity and CVD risk parameters and improving cardiovas-
cular fitness in HAART-treated HIV-infected Africans with
body fat alterations. The beneficial effects of exercise training
are particularly important in sub-Saharan populations, where
the accessibility to HIV treatment is improving, but where min-
imal resources and medications (antihypertensives, antidiabet-
ics, antihyperlipidemics) are available to manage HIV- and
HAART-associated metabolic syndromes that threaten to in-
crease CVD risk.
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